可切除及交界可切除胰腺癌的短程或全新辅助化疗——现状与未来展望
Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives.
作者信息
Labori Knut Jørgen
机构信息
Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
出版信息
Front Surg. 2022 Apr 25;9:839339. doi: 10.3389/fsurg.2022.839339. eCollection 2022.
Abstract
Neoadjuvant therapy improves overall survival compared with a surgery-first approach in patients with borderline resectable pancreatic cancer (BRPC). Evidence of higher quality is required to determine whether neoadjuvant therapy has potential benefits and improves survival for patients with resectable pancreatic cancer (RPC). Most randomized controlled trials (RCTs) have explored short-course neoadjuvant chemotherapy (SNT), but total neoadjuvant chemotherapy (TNT) is now the experimental arm of ongoing RCTs. This article reviews the current status of SNT and TNT in RPC and BRPC, and provides perspectives of future challenges and research directions in this field.
摘要
与手术优先的方法相比，新辅助治疗可提高临界可切除胰腺癌（BRPC）患者的总生存率。需要更高质量的证据来确定新辅助治疗是否对可切除胰腺癌（RPC）患者具有潜在益处并提高生存率。大多数随机对照试验（RCT）都探索了短程新辅助化疗（SNT），但全程新辅助化疗（TNT）目前是正在进行的RCT的试验组。本文综述了RPC和BRPC中SNT和TNT的现状，并提供了该领域未来挑战和研究方向的观点。
相似文献
1
Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives.可切除及交界可切除胰腺癌的短程或全新辅助化疗——现状与未来展望
Front Surg. 2022 Apr 25;9:839339. doi: 10.3389/fsurg.2022.839339. eCollection 2022.
2
Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.比较不同新辅助治疗方案对可切除及临界可切除胰腺癌的疗效和安全性：一项系统评价和网状Meta分析
Eur J Clin Pharmacol. 2023 Mar;79(3):323-340. doi: 10.1007/s00228-022-03441-9. Epub 2022 Dec 28.
3
Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials.新辅助放化疗与直接手术治疗可切除及交界可切除胰腺癌的比较：随机对照试验的Meta分析和试验序贯分析
Ann Hepatobiliary Pancreat Surg. 2023 Feb 28;27(1):28-39. doi: 10.14701/ahbps.22-052. Epub 2022 Dec 20.
4
Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?可切除及边界可切除胰腺癌的新辅助治疗：化疗还是放化疗？
Front Oncol. 2022 Feb 14;11:744161. doi: 10.3389/fonc.2021.744161. eCollection 2021.
5
Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.新辅助化疗（放）疗与手术治疗可切除或交界可切除胰腺癌患者的生存获益：系统评价和荟萃分析。
World J Surg Oncol. 2019 Dec 31;18(1):1. doi: 10.1186/s12957-019-1767-5.
6
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.可切除和交界可切除胰腺癌的新辅助治疗或 upfront 手术：随机对照试验的荟萃分析。
Eur J Cancer. 2022 Jan;160:140-149. doi: 10.1016/j.ejca.2021.10.023. Epub 2021 Nov 24.
7
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.吉西他滨联合白蛋白结合型紫杉醇方案新辅助化疗治疗合并动脉侵犯的可切除边缘胰腺癌：一项前瞻性多中心单臂II期研究方案
Int J Surg Protoc. 2021 Apr 26;25(1):55-60. doi: 10.29337/ijsp.142.
8
Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review.可切除边缘性胰腺癌治疗策略的最新进展：一篇叙述性综述
J Gastrointest Oncol. 2022 Apr;13(2):885-897. doi: 10.21037/jgo-21-829.
9
Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.伴有影像学动脉受累的可切除边缘性胰腺癌的治疗策略
Pancreas. 2016 Nov;45(10):1438-1446. doi: 10.1097/MPA.0000000000000634.
10
Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.新辅助放化疗与边界可切除胰腺癌中淋巴结比率降低相关：倾向评分匹配分析。
Hepatobiliary Pancreat Dis Int. 2021 Feb;20(1):74-79. doi: 10.1016/j.hbpd.2020.08.001. Epub 2020 Aug 17.
引用本文的文献
1
Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better?局部胰腺癌的全新辅助治疗：越多越好吗？
Cancers (Basel). 2024 Jun 30;16(13):2423. doi: 10.3390/cancers16132423.
2
Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.当前关于胰腺导管腺癌外科治疗的争议话题：关于可切除边缘、局部进展期以及同时性或异时性寡转移瘤外科治疗的叙述性综述
J Clin Med. 2023 Oct 11;12(20):6461. doi: 10.3390/jcm12206461.
3
Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress.可切除边缘胰腺癌的综合多模式管理：现状与进展
World J Gastrointest Surg. 2023 Feb 27;15(2):142-162. doi: 10.4240/wjgs.v15.i2.142.
4
3D Ultrasound-Guided Photoacoustic Imaging to Monitor the Effects of Suboptimal Tyrosine Kinase Inhibitor Therapy in Pancreatic Tumors.三维超声引导光声成像监测次优酪氨酸激酶抑制剂疗法对胰腺肿瘤的疗效
Front Oncol. 2022 Jul 7;12:915319. doi: 10.3389/fonc.2022.915319. eCollection 2022.
本文引用的文献
1
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.可切除和边缘可切除胰腺癌的新辅助放化疗与 upfront 手术比较：荷兰随机 PREOPANC 试验的长期结果。
J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27.
2
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.可切除和交界可切除胰腺癌的新辅助治疗或 upfront 手术：随机对照试验的荟萃分析。
Eur J Cancer. 2022 Jan;160:140-149. doi: 10.1016/j.ejca.2021.10.023. Epub 2021 Nov 24.
3
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.局部进展期/交界可切除胰腺癌的新辅助化疗转换。
Ann Surg Oncol. 2022 Mar;29(3):1579-1591. doi: 10.1245/s10434-021-10991-2. Epub 2021 Nov 1.
4
Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival.新辅助化疗后边界可切除和局部进展期胰腺癌的 FDG-PET/CT 代谢活性与生存的关系。
Br J Surg. 2021 Dec 17;109(1):61-70. doi: 10.1093/bjs/znab229.
5
Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives.胰腺癌精准医学的分子与表型分析：当前进展与未来展望
Front Oncol. 2021 Jun 23;11:682872. doi: 10.3389/fonc.2021.682872. eCollection 2021.
6
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.新辅助 FOLFIRINOX 治疗后可切除和边缘可切除胰腺癌放疗的附加价值：系统评价和荟萃分析。
Ann Surg Oncol. 2021 Dec;28(13):8297-8308. doi: 10.1245/s10434-021-10276-8. Epub 2021 Jun 17.
7
The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review.氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描或正电子发射断层扫描/磁共振成像在评估边界性或可切除胰腺癌新辅助治疗反应中的作用：系统文献回顾。
Ann Nucl Med. 2021 Jul;35(7):767-776. doi: 10.1007/s12149-021-01629-0. Epub 2021 May 28.
8
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?胰腺癌的液体活检：我们准备好将其应用于临床实践了吗？
Cancers (Basel). 2021 Apr 20;13(8):1986. doi: 10.3390/cancers13081986.
9
Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.可切除胰腺癌的系统化疗临床试验：综述。
JAMA Surg. 2021 Jul 1;156(7):663-672. doi: 10.1001/jamasurg.2021.0149.
10
Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.新辅助化疗和胰腺切除术后辅助化疗与胰腺导管腺癌生存获益的相关性：一项基于人群的队列研究
Ann Surg Oncol. 2021 Oct;28(11):6790-6802. doi: 10.1245/s10434-021-09823-0. Epub 2021 Mar 30.
Zotero 插件